on the Ovarian cancer; Varied Listed for metastatic from for mCRC, outside Aus and colorectal Feb Dec Bevacizumab Avastin® 11 Yes 48 no-cost funding no funding no funding NZ cancer; 2005 2009 to restrictions grade 4 patient cancers to pay a multiforme for part of the No no Aus and No April No PBAC no Bosutinib Bosulif® 2 No 0 no funding no funding NZ response 2014 application registration Two free cycles Relapsed or rejected in the refractory March no Aus and first 9 Dec no Brentuximab Adcetris® 7 Yes CD30+ 3 2015, no funding no funding NZ cycles 2013 registration Hodgkin then lymphoma Nov free up 2016 to 16 cycles First line metastatic Aus and RAS wild Jan Nov Cetuximab Erbitux® 10 Yes 18 None no funding no funding no funding NZ type 2010 2014, colorectal listed June cancer 2015
Bevacizumab Avastin® Aus and NZ 11 Yes Ovarian cancer; metastatic colorectal cancer; grade 4 multiforme 48 on the Varied from no-cost to patient to pay for part of the Feb 2005 Listed for for mCRC, cancers outside funding restrictions Dec 2009 no funding no funding Bosutinib Bosulif® Aus and NZ 2 No No response 0 No April 2014 No PBAC application no funding no no funding no registration Brentuximab Adcetris® Aus and NZ 7 Yes Relapsed or refractory CD30+ Hodgkin lymphoma 3 Two free cycles in the first 9 cycles then free up to 16 cycles Dec 2013 March 2015, Nov 2016 no funding no no funding no registration Cetuximab Erbitux® Aus and NZ 10 Yes First line metastatic RAS wild type colorectal cancer 18 None Jan 2010 Nov 2014, listed June 2015 no funding no funding no funding rejected a